HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $380 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals (VRTX) and maintained a $380 price target.
June 12, 2023 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals and maintained a $380 price target.
The reiteration of a Buy rating and a maintained price target of $380 by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for Vertex Pharmaceuticals. This news is likely to have a positive short-term impact on the stock price, as it shows confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100